- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
- Interventions
- Betahistine, Placebo Oral Tablet
- Drug
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Orangeburg, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Autism-Related Irritability
- Interventions
- KarXT, KarX-EC
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 51
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more
- Conditions
- Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
- Interventions
- MINI-KID
- Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Autism Spectrum Disorder (ASD), Cardiometabolic Health Indicators, Cardiometabolic Risk Factors, Metabolic Syndrome, Prediabetes
- Interventions
- Not listed
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Schizophrenia, Autism
- Interventions
- Lurasidone
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
- Conditions
- Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD, Autism Spectrum Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Interventions
- Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo
- Drug
- Lead sponsor
- Maria de las Mercedes Perez Rodriguez
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Autistic Disorder, Pervasive Developmental Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Rett Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Interventions
- Lumateperone
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
- Conditions
- Autism, Intellectual Disabilities With Other Behavioral Symptoms, Intellectual Disability
- Interventions
- Regulating Together group therapy
- Behavioral
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
- Interventions
- Latuda©
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 6 Years to 19 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina